ProShare Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-32,469
| Closed | -$120K | – | 1799 |
|
|
2017
Q4 | $120K | Buy |
+32,469
| New | +$133K | ﹤0.01% | 1718 |
|
|
2016
Q4 | – | Sell |
-14,178
| Closed | -$140K | – | 1769 |
|
|
2016
Q3 | $140K | Buy |
14,178
+2,396
| +20% | +$17K | ﹤0.01% | 1389 |
|
|
2016
Q2 | $67K | Sell |
11,782
-1,781
| -13% | -$12.1K | ﹤0.01% | 1544 |
|
|
2016
Q1 | $103K | Sell |
13,563
-1,463
| -10% | -$11.3K | ﹤0.01% | 1519 |
|
|
2015
Q4 | $200K | Buy |
+15,026
| New | +$259K | ﹤0.01% | 1546 |
|
|
2015
Q3 | – | Sell |
-2,152
| Closed | -$48K | – | 1618 |
|
|
2015
Q2 | $48K | Sell |
2,152
-882
| -29% | -$14K | ﹤0.01% | 1607 |
|
|
2015
Q1 | $30K | Buy |
3,034
+144
| +5% | +$1.41K | ﹤0.01% | 1894 |
|
|
2014
Q4 | $33K | Sell |
2,890
-1,794
| -38% | -$19.5K | ﹤0.01% | 1944 |
|
|
2014
Q3 | $54K | Sell |
4,684
-1,062
| -18% | -$16.2K | ﹤0.01% | 2256 |
|
|
2014
Q2 | $112K | Buy |
+5,746
| New | +$101K | ﹤0.01% | 2331 |
|
|
2013
Q4 | – | Sell |
-3,715
| Closed | -$46K | – | 2167 |
|
|
2013
Q3 | $46K | Sell |
3,715
-4,301
| -54% | -$45.3K | ﹤0.01% | 2508 |
|
|
2013
Q2 | $75K | Buy |
+8,016
| New | +$103K | ﹤0.01% | 2314 |
|
ProShare Advisors's CASC Position: Q1 2018 in Review
ProShare Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 32,469 shares — an estimated $120K sold.
ProShare Advisors first reported a position in CASC in Q2 2013 and held it in 12 quarters. The position peaked at $200K in Q4 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- ProShare Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- ProShare Advisors sold 32,469 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $120K.
- ProShare Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
- ProShare Advisors's Cascadian Therapeutics, Inc. position peaked at $200K in Q4 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on ProShare Advisors's 13F filing for Q1 2018, filed 14 May 2018.